AR081925A1 - Uso de ranolazina para el tratamiento de la hipertension pulmonar - Google Patents
Uso de ranolazina para el tratamiento de la hipertension pulmonarInfo
- Publication number
- AR081925A1 AR081925A1 ARP110102063A ARP110102063A AR081925A1 AR 081925 A1 AR081925 A1 AR 081925A1 AR P110102063 A ARP110102063 A AR P110102063A AR P110102063 A ARP110102063 A AR P110102063A AR 081925 A1 AR081925 A1 AR 081925A1
- Authority
- AR
- Argentina
- Prior art keywords
- ranolazine
- treatment
- pulmonary hypertension
- patient
- pulmonary
- Prior art date
Links
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 title abstract 2
- 208000002815 pulmonary hypertension Diseases 0.000 title abstract 2
- 229960000213 ranolazine Drugs 0.000 title abstract 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 abstract 1
- 102000002045 Endothelin Human genes 0.000 abstract 1
- 108050009340 Endothelin Proteins 0.000 abstract 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 229940097217 cardiac glycoside Drugs 0.000 abstract 1
- 239000002368 cardiac glycoside Substances 0.000 abstract 1
- 229960005156 digoxin Drugs 0.000 abstract 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 abstract 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 229930002534 steroid glycoside Natural products 0.000 abstract 1
- 150000008143 steroidal glycosides Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 229940124549 vasodilator Drugs 0.000 abstract 1
- 239000003071 vasodilator agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Tratamiento de pacientes que padecen hipertensión pulmonar, tal como hipertensión arterial pulmonar (HAP), o síntomas asociados con dicha enfermedad, administrando una cantidad terapéuticamente eficaz de ranolazina o una sal o sales de la misma al paciente.Reivindicación 21: El método de acuerdo con cualquiera de las reivindicaciones precedentes, en el cual también se administra al paciente un agente terapéutico adicional seleccionado entre el grupo integrado por glucósidos cardíacos, vasodilatadores/bloqueadores de canales de calcio, digoxina, un anticoagulante, un diurético, protacicIina, un antagonista de los receptores de endotelina y un inhibidor de fosfodiesterasa, o una combinación de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35546210P | 2010-06-16 | 2010-06-16 | |
| US40786410P | 2010-10-28 | 2010-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081925A1 true AR081925A1 (es) | 2012-10-31 |
Family
ID=44202215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102063A AR081925A1 (es) | 2010-06-16 | 2011-06-14 | Uso de ranolazina para el tratamiento de la hipertension pulmonar |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120004188A1 (es) |
| EP (1) | EP2582372A1 (es) |
| JP (1) | JP2013528649A (es) |
| AR (1) | AR081925A1 (es) |
| AU (1) | AU2011267871A1 (es) |
| CA (1) | CA2801707A1 (es) |
| TW (1) | TW201215392A (es) |
| UY (1) | UY33453A (es) |
| WO (1) | WO2011159706A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4546824B2 (ja) | 2002-05-21 | 2010-09-22 | ギリアード・パロ・アルト・インコーポレイテッド | 糖尿病を処置する方法 |
| US20130245469A1 (en) * | 2012-03-19 | 2013-09-19 | Cardiomems, Inc. | Pulmonary Arterial Hemodynamic Monitoring for Chronic Obstructive Pulmonary Disease Assessment and Treatment |
| JP6329957B2 (ja) | 2012-10-26 | 2018-05-23 | キエージィ ファーマチェウティチ エス．ペー．アー． | 心不全において血圧を制御するためおよび呼吸困難を低減させるための方法 |
| EP2922465A4 (en) | 2012-11-21 | 2016-07-06 | Cardiomems Inc | DEVICES, SYSTEMS AND METHODS FOR ASSESSING AND TREATING PULMONARY ARTERIAL HYPERTENSION (PAH) |
| WO2014145712A1 (en) | 2013-03-15 | 2014-09-18 | Cardiomems, Inc. | Methods for the treatment of cardiovascular conditions |
| KR20190005708A (ko) * | 2017-07-05 | 2019-01-16 | 이화여자대학교 산학협력단 | 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4567264A (en) * | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5455045A (en) | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| US6303607B1 (en) | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
| JP2008526879A (ja) | 2005-01-06 | 2008-07-24 | シーブイ・セラピューティクス・インコーポレイテッド | ラノラジンを含有する徐放性薬学的処方物 |
| US20100010024A1 (en) * | 2006-07-01 | 2010-01-14 | Bayer Healthcare Ag | Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension |
| WO2010068461A1 (en) | 2008-11-25 | 2010-06-17 | Gilead Palo Alto, Inc. | Co-administration of ranolazine and cardiac glycosides |
-
2011
- 2011-06-10 TW TW100120385A patent/TW201215392A/zh unknown
- 2011-06-14 JP JP2013515456A patent/JP2013528649A/ja not_active Withdrawn
- 2011-06-14 AR ARP110102063A patent/AR081925A1/es unknown
- 2011-06-14 UY UY0001033453A patent/UY33453A/es not_active Application Discontinuation
- 2011-06-14 CA CA2801707A patent/CA2801707A1/en not_active Abandoned
- 2011-06-14 WO PCT/US2011/040363 patent/WO2011159706A1/en active Application Filing
- 2011-06-14 AU AU2011267871A patent/AU2011267871A1/en not_active Abandoned
- 2011-06-14 EP EP11726037.2A patent/EP2582372A1/en not_active Withdrawn
- 2011-06-14 US US13/160,393 patent/US20120004188A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20120004188A1 (en) | 2012-01-05 |
| UY33453A (es) | 2012-01-31 |
| WO2011159706A1 (en) | 2011-12-22 |
| JP2013528649A (ja) | 2013-07-11 |
| TW201215392A (en) | 2012-04-16 |
| CA2801707A1 (en) | 2011-12-22 |
| EP2582372A1 (en) | 2013-04-24 |
| AU2011267871A1 (en) | 2013-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081925A1 (es) | Uso de ranolazina para el tratamiento de la hipertension pulmonar | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| NI201700032A (es) | Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del higado graso no alcohólico | |
| EP2512479A4 (en) | METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | |
| CR9181A (es) | Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa | |
| MX2015001115A (es) | Derivativos de piperidina fusionados con espiro para usarse como inhibidores del canal de potasio medular externo renal. | |
| BR112015025464A2 (pt) | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico | |
| JP2016508134A5 (es) | ||
| NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| PE20081150A1 (es) | Inhibidores de dipetidilpeptidasa | |
| BR112012005225B8 (pt) | Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente | |
| BR112015020209A2 (pt) | uso de linagliptina em terapia antidiabética de proteção cardíaca e renal | |
| EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
| NI200800169A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor | |
| CO6470887A2 (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona. | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
| AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
| AR065731A1 (es) | Composiciones farmaceuticas que contienen 2-[6-(3-amino-pipenidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-primidin-1-il metil]-4-fluoro-benzonitrilo. uso. metodo de tratamiento, administracion semanal de inhibidores de la dipeptidilpeptidasa. | |
| BR112014003071A2 (pt) | tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical | |
| CL2011000806A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |